blood as a dimer with a 2-hour half-life. 3 It has been reported that the steady state of VWFpp to VWF antigen (VWF:Ag) ratio (VWFpp/VWF:Ag) may be an indicator of degree of VWF clearance. [4] [5] [6] An increased VWFpp/VWF:Ag indicates an enhanced VWF clearance, which has been described in both patients with von Willebrand disease (VWD) and acquired von Willebrand syndrome (AVWS).
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VWD, inherited in an autosomal dominant or recessive fashion, is the most common congenital bleeding disorder. Because different mutations can affect VWF, resulting in variable impact on circulating levels and activities of VWF, clinical symptoms of VWD vary from mild to severe. The classification of VWD in different forms reflects these heterogeneous causal mechanisms, and it is often challenging.
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Among VWD variants, VWD type 1 Vicenza is an extreme example of increased VWF clearance. Compared with healthy controls, the half-life of VWF type 1 Vicenza is shortened 4.4-fold after desmopressin, 11 thus suggesting that rapid clearance of VWF accounts for the moderately severe plasma deficiency of this disease variant. VWD type 1 Vicenza is also characterized by proportionately low levels of VWF:Ag and VWF:RCo, ultra-large plasma VWF multimers, and normal platelet levels of VWF. 12 Although low, VWF:Ag and VWF:RCo levels are decreased proportionately, 13 so that VWF:RCo/VWF:Ag ratios are not reduced, and the Vicenza variant is therefore classified among VWD type 1. AVWS is a rare, often underdiagnosed syndrome, characterized by quantitative, structural, or functional VWF defects that are acquired (i.e., not inherited), and often accompanied by a severe bleeding tendency. AVWS can be associated with different underlying diseases, including lymphoproliferative diseases, autoimmune disorders, and monoclonal gammopathies. [14] [15] [16] The International Society of Thrombosis and Haemostasis (ISTH) registry reported that the highest frequency of AVWS occurs in elderly patients, with a median age at diagnosis of 62 years. 17 Frequently, the mechanism responsible for AVWS is increased VWF clearance by autoantibodies. 18 Because laboratory results in AVWS are similar to those in VWD, and include decreased plasma levels of VWF:Ag and VWF:RCo, it is often difficult to make a differential diagnosis between VWD and AVWS because the available diagnostic laboratory tests do not provide adequate information and the personal history of bleeding (acquired or lifelong) is not always conclusive. Therefore, a diagnostic biomarker may facilitate the differential diagnosis and subsequent management of these two disorders, both due to deficiency and dysfunction of VWF.
With this background and gaps of knowledge, the aim of this cross-sectional study was to evaluate the ability of VWFpp/VWF:Ag to differentiate VWD from the AVWS, either using this ratio alone or in combination with further laboratory evaluations. 
Patients and Methods

Patients
Statistical Analysis
Continuous variables were described as median with interquartile range (IQR), categorical variables as counts, and percentages. Because patients with VWD type 1 Vicenza and AVWS are characterized by a markedly increased clearance of VWF, our first step was to evaluate whether or not VWFpp/VWF:Ag could discriminate between patients with a modestly increased VWF clearance (most VWD cases) and those with a markedly increased VWF clearance (AVWS and type 1 Vicenza). For this purpose, in the frame of a logistic regression model, a receiver operating characteristic (ROC) curve was used to assess the optimal cutoff of VWFpp/VWF: Ag for their discrimination. This was identified as the value with the best compromise between sensitivity and specificity (Youden's index). An internal validation of the predictive model was performed with 1,000 bootstrap replicates to 
Results
Baseline characteristics of the main patient groups are shown in ►Table 1. VWD patients were categorized into type 1 Vicenza (n ¼ 14), VWD type 1 (Vicenza excluded; The genetic analysis of the mutation at codon 1205 in the group with the markedly increased VWF clearance allowed us to distinguish between VWD type 1 Vicenza (characterized by the presence of the mutation p.R1205H) and AVWS (absence of this mutation).
Discussion
In this study, we measured VWFpp/VWF:Ag in 153 nonconsecutive patients with VWD or AVWS, to assess the potential diagnostic role of this marker in the differential diagnosis VWFpp for Differential Diagnosis between VWD and AVWS Stufano et al. 39 VWFpp for Differential Diagnosis between VWD and AVWS Stufano et al. 40 between these two diseases. We found that VWFpp/VWF:Ag was markedly increased in cases characterized by higher VWF plasma clearance (i.e., AVWS and VWD type 1 Vicenza), as already reported. [4] [5] [6] [7] [8] [9] Most of the remaining VWD types, characterized by lower VWF clearance, invariantly had a VWFpp/VWF:Ag higher than the upper level of laboratory reference range (0.6-1.6), but generally less than those of AVWS and VWD type 1 Vicenza. Therefore, in the present study, we confirm the role of VWFpp/VWF:Ag as a tool for the diagnosis of both VWD and AVWS, because we found an increased value of this marker in the majority of patients included in our investigation. On the contrary, VWFpp/VWF: Ag was of little utility in the subclassification of other VWD types. Therefore, very high levels of the VWFpp/VWF:Ag should raise the suspicion of either AVWS or VWD type 1 Vicenza (i.e., the two groups of patients with the highest VWFpp/VWF:Ag in this study).
We also evaluated the potential diagnostic efficiency of VWFpp/VWF:Ag to discriminate patients with modestly increased VWF clearance (most VWD) from those with a markedly increased clearance (AVWS and VWD type 1 Vicenza). At values of 3.9 or higher, the VWFpp/VWF:Ag had a good discriminative power in identifying AVWS and VWD type 1 Vicenza, which was even better after excluding eight patients in the group of AVWS with the lowest VWFpp/VWF: Ag (i.e., those with ET; from an AUC of 0.88-0.96). The AUC of VWD (type 1 Vicenza excluded) versus AVWS and VWD versus type 1 Vicenza showed a good discriminative capability as well.
For the subsequent discrimination between AVWS and VWD type 1 Vicenza, we found that the genetic analysis for the identification of p.R1205H mutation in exon 27 of VWF was necessary, as shown in the present study. This study demonstrated that the good discrimination of patients with a markedly increased from those with a modestly increased VWF clearance based on the VWFpp/VWF:Ag values allowed the possibility to limit genetic analysis only to a minority of cases (one-third of patients in our study). Type Vicenza cases were confirmed by genetic analysis enabling the identification of both M740I (G2220A) and R1205H (G3614A) mutations in exons 17 and 27 of VWF.
This study has some limitations. As it included nonconsecutive patients, there is a possible relevant inherent selection bias. Second, the diagnostic utility of screening for VWFpp/VWF:Ag in consecutive patients with suspected VWD or AVWS has not yet been assessed, as this study included only selected patients with a confirmed diagnosis of VWD or AVWS. Second, we could not calculate the predictive values of our model, as they are influenced by disease prevalence, which could not be correctly estimated due to the study design. Another limitation is the small sample size of some subgroups of AVWS patients (i.e., cardiovascular disease and lymphoproliferative disorders subgroups).
Conclusion
VWFpp/VWF:Ag is a helpful tool to discriminate between patients with a markedly increased VWF clearance (AVWS or type 1 Vicenza) from those with a modestly increased clearance (most VWD patients), but molecular analysis is subsequently needed to finalize the differential diagnosis between AVWS and VWD type 1 Vicenza. Indeed, a markedly increased VWFpp/VWF:Ag will likely point to either VWD type 1 Vicenza or non-ET-associated AVWS. Larger studies with consecutive patient enrolment will be needed to confirm these preliminary findings.
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